RAD-140 vs LGD-4033: Androgen-Receptor Research Compared
Testolone vs Ligandrol: Mechanisms, Evidence and Research Differences
RAD-140 Testolone and LGD-4033 Ligandrol are frequently compared in searches for RAD-140 vs LGD-4033, Testolone vs Ligandrol, strongest SARM research and SARMs for muscle-growth research. Both compounds are genuine non-steroidal selective androgen receptor modulators, but their chemical structures, development histories and published evidence are not identical.
The central scientific difference is not simply that one compound is “stronger.” LGD-4033 has a comparatively developed clinical evidence base involving pharmacokinetics, lean body mass and selected biochemical markers. RAD-140 has extensive discovery and preclinical characterisation, alongside a later Phase 1 study conducted in an oncology setting. Those evidence streams cannot be treated as interchangeable.
Researchers comparing RAD-140 research with LGD-4033 research must therefore examine the experimental model, study duration, selected endpoints, comparator, analytical method and evidence quality before interpreting reported outcomes.
This article compares the two compounds strictly as laboratory research materials. It does not provide personal-use guidance, dosing information, cycles, stacking instructions or performance advice.
What Are RAD-140 Testolone and LGD-4033 Ligandrol?
RAD-140 and LGD-4033 belong to the selective androgen receptor modulator class. SARMs were developed to investigate whether androgen-receptor signalling could be directed towards selected tissues while reducing activity in other androgen-responsive systems.
The androgen receptor is a nuclear receptor. When an appropriate ligand binds to it, the receptor undergoes a conformational change, interacts with regulatory proteins and can influence transcription at androgen-responsive genes. This means SARM activity involves more than simple receptor binding. The final cellular response depends on ligand structure, receptor conformation, co-regulator recruitment, tissue context, concentration and exposure time.
RAD-140 is also known as Testolone, Vosilasarm and EP0062. It was described in the scientific literature as a potent, orally bioavailable, non-steroidal SARM developed for tissue-selective anabolic-androgenic research.
LGD-4033 is also known as Ligandrol and has been developed under the name VK5211. It is another orally active, non-steroidal androgen-receptor ligand investigated across preclinical and controlled clinical research.
Both compounds are experimental. Neither is an approved medicine, food or dietary supplement, and both are prohibited in competitive sport.
RAD-140 vs LGD-4033 Chemical Structure
RAD-140 and LGD-4033 act through the same broad receptor family but are chemically distinct molecules. Their shared SARM classification should not be interpreted as evidence that they have identical binding, metabolism or tissue-response profiles.
RAD-140 Testolone Molecular Characteristics
RAD-140 has the molecular formula C₂₀H₁₆ClN₅O₂ and an approximate molecular weight of 393.83 g/mol. Its structure contains a chlorinated aromatic system, nitrile groups and an oxadiazole ring.
Principal RAD-140 identifiers include:
Compound name—RAD-140
Common name—Testolone
Alternative development name—Vosilasarm or EP0062
Chemical class—Non-steroidal selective androgen receptor modulator
Molecular formula—C₂₀H₁₆ClN₅O₂
Approximate molecular weight—393.83 g/mol
Primary research target—Androgen receptor
The BioPlex RAD-140 Testolone 50x15mg research compound is supplied in a defined capsule format for controlled analytical and laboratory investigation.
LGD-4033 Ligandrol Molecular Characteristics
LGD-4033 has the molecular formula C₁₄H₁₂F₆N₂O and an approximate molecular weight of 338.25 g/mol. Its molecular structure contains multiple fluorine atoms, a nitrile group, a pyrrolidine ring and a hydroxyl group.
Principal LGD-4033 identifiers include:
Compound name—LGD-4033
Common name—Ligandrol
Development name—VK5211
Chemical class—Non-steroidal selective androgen receptor modulator
Molecular formula—C₁₄H₁₂F₆N₂O
Approximate molecular weight—338.25 g/mol
Primary research target—Androgen receptor
The BioPlex LGD-4033 Ligandrol 50x15mg research compound provides a separately identified capsule format for comparative laboratory research.
These structural differences matter because molecular size, stereochemistry, functional groups and physicochemical properties can influence receptor interaction, metabolic transformation and experimental behaviour.
How RAD-140 and LGD-4033 Interact With the Androgen Receptor
Both compounds bind to the androgen receptor, but selective modulation does not mean that activity is restricted to only one tissue. The term describes a research objective and a pattern of relative activity rather than an absolute biological boundary.
After ligand binding, the androgen receptor can move within the cell, interact with DNA-associated regulatory regions and recruit co-activators or co-repressors. A ligand-dependent receptor conformation can change which regulatory proteins are recruited. This helps explain why separate androgen-receptor ligands may produce different transcriptional profiles even when they share the same primary receptor target.
Variables affecting the observed response include:
Androgen-receptor expression
Cell type and tissue model
Co-regulator abundance
Ligand concentration
Exposure duration
Metabolic stability
Gene-expression endpoint
Comparator compound
Species and experimental preparation
RAD-140 was selected during discovery research for strong androgen-receptor activity and tissue-selective effects in preclinical models. LGD-4033 was also developed to investigate anabolic activity with a differentiated tissue-response profile.
However, receptor affinity alone does not establish which compound will produce a larger effect in every model. Binding measurements, cell-based transcription assays, animal models and clinical endpoints each measure different layers of activity.
What RAD-140 Research Studies Show
The original RAD-140 discovery paper described its design, synthesis and preclinical characterisation. Researchers reported androgen-receptor activity, oral bioavailability and tissue-selective anabolic-androgenic findings across laboratory and animal models.
Early preclinical work examined endpoints involving muscle-associated tissue, prostate-associated tissue, bone and central nervous system models. These findings helped establish RAD-140 as a distinctive non-steroidal androgen-receptor modulator, but they should not be presented as direct proof of universal outcomes beyond the tested models.
RAD-140 was later studied in a Phase 1 oncology programme under the name Vosilasarm. That research examined safety, tolerability, pharmacokinetics and preliminary anti-tumour activity in a specific androgen-receptor-positive, oestrogen-receptor-positive breast-cancer setting. This study is scientifically important because it provides direct clinical pharmacology information, but its participants, objectives and disease context differ substantially from muscle-growth research.
A 2025 preclinical investigation also examined RAD-140 with functional overload in a rodent skeletal-muscle model. The researchers did not find evidence that RAD-140 produced an additional hypertrophic effect beyond functional overload under the specific conditions tested. This result is valuable precisely because it demonstrates why mechanistic expectations should not be treated as guaranteed experimental outcomes.
The RAD-140 evidence base therefore includes:
Compound discovery and synthesis research
Androgen-receptor binding and activation studies
Preclinical anabolic-androgenic models
Tissue-selectivity investigations
Neurobiological preclinical research
Phase 1 oncology pharmacology
Recent skeletal-muscle preclinical investigation
RAD-140 is scientifically notable, but its popular reputation as the automatically “strongest SARM” extends beyond what comparative controlled evidence can establish.
What LGD-4033 Research Studies Show
LGD-4033 has a stronger direct evidence base for controlled lean-tissue and pharmacokinetic research.
A published randomised, placebo-controlled investigation evaluated LGD-4033 over 21 days. The study examined safety observations, pharmacokinetics, hormone-related variables, lipid markers, lean body mass and physical-performance endpoints across several controlled groups.
The study reported a dose-related increase in lean body mass over the short experimental period. It also documented dose-related changes in selected endocrine and lipid variables. Measures such as fat mass and physical function did not show the same clear pattern of change during the limited study duration.
This distinction is essential. A change in lean body mass is not identical to a demonstrated improvement in strength, function, long-term tissue quality or clinical outcome. Lean-mass measurements can also reflect several tissue and fluid components depending on the method used.
LGD-4033 research additionally produced pharmacokinetic data indicating a relatively long elimination profile and accumulation with repeated exposure. Pharmacokinetic findings help researchers understand concentration over time, but they are not proof of beneficial biological outcomes.
Later development under the VK5211 name investigated recovery-associated lean-body-mass endpoints in a hip-fracture study population. Publicly reported results added to the compound’s clinical-development history, although the full evidence must still be interpreted in relation to study design, population, endpoint selection and publication status.
The LGD-4033 evidence base includes:
Preclinical androgen-receptor research
Pharmacokinetic studies
Randomised placebo-controlled research
Lean-body-mass endpoints
Endocrine and lipid marker analysis
Physical-function measurements
Later clinical-development research under VK5211
Compared with RAD-140, LGD-4033 has more direct controlled evidence involving lean-tissue measurements. That does not establish that LGD-4033 is universally superior; it means researchers have a stronger published basis for interpreting certain endpoints.
RAD-140 vs LGD-4033 for Muscle-Growth Research
The phrase RAD-140 vs LGD-4033 for muscle growth can conceal several different research questions.
Muscle-growth research may examine:
Cellular protein-synthesis signalling
Myogenic gene expression
Muscle-fibre cross-sectional area
Whole-muscle mass
Lean body mass
Nitrogen balance
Strength or force production
Functional performance
Recovery following experimental injury
These are related endpoints, but they are not equivalent.
RAD-140 has compelling preclinical androgen-receptor and tissue-selectivity data. LGD-4033 has the clearer controlled clinical signal for short-term lean-body-mass change. A scientifically responsible comparison should therefore say:
RAD-140—strong discovery and preclinical characterisation, with limited directly comparable lean-tissue clinical evidence
LGD-4033—more developed controlled clinical evidence for pharmacokinetics and lean-body-mass endpoints
Neither compound—proven to be the universal strongest SARM across every muscle-growth model
Researchers should avoid converting a difference in evidence quantity into an unsupported claim about absolute biological potency.
Testolone vs Ligandrol Evidence Quality
Evidence quality is determined by more than whether a result appears in a scientific paper.
RAD-140 Evidence Strengths
RAD-140 benefits from detailed discovery chemistry, preclinical receptor characterisation and multiple tissue models. The compound has also entered clinical research in a specialised oncology context.
RAD-140 Evidence Limitations
Much of the muscle-associated interpretation remains preclinical. Direct controlled evidence for lean-tissue outcomes is comparatively limited, and oncology findings cannot be transferred automatically to general body-composition research.
LGD-4033 Evidence Strengths
LGD-4033 has published randomised, placebo-controlled data involving pharmacokinetics, lean body mass and biochemical endpoints. This provides a stronger framework for assessing short-term controlled findings.
LGD-4033 Evidence Limitations
The best-known published controlled study was short and involved a limited sample. Lean-body-mass change did not establish a corresponding universal improvement in strength or physical function. Longer-term safety and outcome questions remain unresolved.
Why No Direct Winner Can Be Declared
There is no robust head-to-head trial in which RAD-140 and LGD-4033 were compared under identical conditions across a broad set of muscle, functional, endocrine and safety endpoints. Claims that one is definitively stronger generally combine results from different models or rely on non-scientific reports.
Cross-study comparison is weakened when studies differ in:
Population or species
Experimental duration
Compound exposure
Outcome measurement
Control selection
Tissue preparation
Statistical power
Research objective
The absence of a direct comparison is one of the most important conclusions in the RAD-140 or LGD-4033 question.
RAD-140 vs LGD-4033 Pharmacokinetic Research
Pharmacokinetics describes what happens to a compound across absorption, distribution, metabolism and elimination. It is distinct from pharmacodynamics, which examines what the compound does within the biological system.
LGD-4033 has published controlled pharmacokinetic data showing concentration-related exposure and a relatively prolonged elimination profile. These data allow researchers to model exposure more directly.
RAD-140 was described as orally bioavailable in preclinical development, and later oncology research generated additional pharmacokinetic information. However, the available literature does not provide a simple basis for claiming that its exposure profile makes it inherently better for muscle research.
Differences in analytical sampling, biological matrix, participant population and study design prevent casual comparisons of half-life figures gathered from unrelated sources.
For laboratory research, pharmacokinetic interpretation should remain connected to validated analytical methods, sampling intervals and the exact compound identity.
Endocrine, Lipid and Safety-Related Research Variables
Selective androgen-receptor modulation does not mean an absence of systemic biological effects. The androgen receptor participates in multiple tissues and regulatory networks.
LGD-4033 controlled research reported dose-related changes in selected hormone and lipid measures. These observations are relevant because they show that tissue-selective design does not isolate the compound from wider endocrine physiology.
RAD-140 research has also generated safety and tolerability observations, particularly through its oncology development. However, the population and research objective differ from those used in LGD-4033 body-composition research.
Relevant research variables include:
Androgen-responsive gene expression
Endocrine feedback markers
Lipid measures
Liver-associated laboratory variables
Haematological measures
Body-composition endpoints
Functional outcomes
Tissue-specific histology
Compound exposure and metabolites
Long-term evidence remains incomplete for both compounds. Neither should be described as scientifically established as safe for personal consumption.
Analytical Identity When Comparing RAD-140 and LGD-4033
Because RAD-140 and LGD-4033 are chemically distinct, accurate product identification is essential in laboratory research.
High-performance liquid chromatography can help assess sample composition and relative purity under a defined method. Mass spectrometry can support identity by examining mass-to-charge signals consistent with the expected molecule. Neither method should be interpreted beyond the sample and procedure actually tested.
Researchers comparing RAD-140 and LGD-4033 should check:
Compound name and synonym
Molecular formula
Expected molecular mass
Batch or sample identifier
Analytical method
Testing date
Reported purity
Connection between the report and supplied batch
Capsule strength and count
BioPlex provides additional information about its independent testing route through BioPlex Peptide Testing and Vanguard Laboratory.
Is RAD-140 Stronger Than LGD-4033?
There is no scientifically established universal answer.
If “stronger” means having more direct published controlled evidence for lean-body-mass change, LGD-4033 currently has the clearer evidence base.
If “stronger” refers to discovery-stage androgen-receptor activity or selected preclinical anabolic-androgenic models, RAD-140 has attracted substantial research interest.
If “stronger” means superior functional outcomes, long-term safety, a larger effect across every tissue or a better result in a direct head-to-head comparison, the evidence is insufficient.
The correct conclusion depends on the endpoint:
Receptor research—both are genuine androgen-receptor modulators
Preclinical characterisation—RAD-140 has detailed discovery-stage evidence
Controlled lean-tissue research—LGD-4033 has the stronger published record
Direct comparative superiority—not established
Long-term safety—not established
This endpoint-based interpretation is more accurate than repeating online rankings of the “strongest SARM.”
RAD-140 or LGD-4033 for Laboratory Investigation?
Selection should be driven by the research question rather than commercial reputation.
RAD-140 may be relevant to models examining:
Androgen-receptor ligand design
Tissue-selective transcription
Preclinical anabolic-androgenic separation
Androgen-receptor-positive oncology pathways
Skeletal-muscle responses in controlled preclinical models
LGD-4033 may be relevant to models examining:
Androgen-receptor pharmacology
Lean-tissue endpoints
Pharmacokinetics and exposure
Endocrine feedback markers
Lipid variables
Body-composition measurement
A comparative experiment would require appropriate controls, validated analytical identity, matched exposure logic, pre-specified endpoints and careful interpretation. It should not assume that the same nominal concentration produces equivalent receptor occupancy or tissue exposure for both compounds.
Frequently Asked Questions About RAD-140 vs LGD-4033
Are RAD-140 and LGD-4033 both genuine SARMs?
Yes. Both are non-steroidal selective androgen receptor modulators investigated for androgen-receptor signalling. This distinguishes them from compounds such as MK-677, which is a ghrelin-receptor agonist rather than a SARM.
What is the main difference between RAD-140 and LGD-4033?
They have different chemical structures and research histories. RAD-140 has extensive discovery and preclinical characterisation, while LGD-4033 has stronger published controlled evidence involving pharmacokinetics and lean-body-mass endpoints.
Is Testolone the same as RAD-140?
Testolone is the common name widely used for RAD-140. Vosilasarm and EP0062 are additional identifiers associated with the compound’s development.
Is Ligandrol the same as LGD-4033?
Yes. Ligandrol is the common name used for LGD-4033. The compound has also been developed under the identifier VK5211.
Which has more muscle-growth research evidence?
LGD-4033 has stronger direct controlled evidence for lean-body-mass endpoints. RAD-140 has substantial preclinical anabolic-androgenic research, but the two compounds have not been compared adequately in a direct head-to-head study.
Can lean body mass be treated as proof of greater strength?
No. Lean body mass and functional strength are separate endpoints. A change in one does not automatically establish a corresponding change in the other.
Are RAD-140 and LGD-4033 approved supplements?
No. They are experimental research compounds, not approved dietary supplements, foods or medicines. Both are prohibited in competitive sport.
Does BioPlex provide RAD-140 and LGD-4033 research capsules?
BioPlex lists both RAD-140 Testolone 50x15mg and LGD-4033 Ligandrol 50x15mg as defined research-capsule formats. They are supplied strictly for laboratory research and analytical reference.
Conclusion
RAD-140 Testolone and LGD-4033 Ligandrol are genuine non-steroidal selective androgen receptor modulators, but the RAD-140 vs LGD-4033 comparison cannot be reduced to a universal ranking.
RAD-140 has a strong discovery and preclinical foundation. Its research history includes androgen-receptor activity, tissue-selectivity models, anabolic-androgenic investigation, oncology pharmacology and more recent skeletal-muscle research. These studies make RAD-140 an important compound for examining selective androgen signalling, but much of its muscle-associated evidence remains preclinical.
LGD-4033 has the clearer controlled evidence base for pharmacokinetics and lean-body-mass endpoints. Published placebo-controlled research provides direct measurements of compound exposure, body composition and selected endocrine and lipid variables. However, short-term lean-body-mass change is not the same as proof of improved strength, function, long-term safety or universal superiority.
The most defensible conclusion is therefore endpoint-specific. RAD-140 is particularly notable for its detailed preclinical characterisation. LGD-4033 is better supported for controlled lean-tissue and pharmacokinetic research. Neither has been proven to be the strongest SARM across every experimental setting, and no adequate direct head-to-head study establishes a definitive winner.
Researchers should compare chemical identity, experimental design, study quality, selected endpoint and evidence limitations before interpreting either compound.
Continue Exploring...
View RAD-140 Testolone 50x15mg Research Compound ⟶
View LGD-4033 Ligandrol 50x15mg Research Compound ⟶
Explore BioPlex SARMs Capsules and Related Research Compounds ⟶
Read Best SARMs for Muscle Growth: Top 3 Research Compounds Compared ⟶
Read MK-677 vs RAD-140: Ibutamoren vs Testolone Research Compared ⟶
Review BioPlex Independent Testing Support ⟶
All discussion is presented strictly for educational and scientific research purposes only, supporting informed study, data interpretation, and responsible laboratory investigation.
